Login
Corvus Pharmaceuticals NASDAQ: CRVS
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
| Name | Corvus Pharmaceuticals |
| Ticker | CRVS |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
2.25
2.18 / 4.86 |
| Momentum | Weak Down |
| Market cap | 86 M |
| 1Y Total Return |
-47.55 %
Subpar |
| 1Y Volatility |
68.57 %
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
Details
| Ticker | CRVS |
| Name | Corvus Pharmaceuticals |
| ISIN | US2210151005 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 07/23/2021
| Close Price | 2.25 |
| 52W Low/High | 2.18 / 4.86 |
| Market cap | 86 M |
| 1Y Total Return |
-47.55 %
Subpar |
| 1Y Volatility |
68.57 %
High Risk |
| Beta | 3.20 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -2.46 |
| Diluted Earnings / Share | -0.10 |
| ROE | - |
| ROIC | -10.5 % |
| Price / Revenue | - |
| Price / Book | 0.8 |
| Price / CF | -2.3 |
| Current Ratio | 4.9 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.02 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
-
|
-
|
-
|
-
|
-
|
-
|
|
| R&D |
30
|
39
|
36
|
45
|
37
|
15
|
|
| EBITDA |
-4
|
-47
|
-43
|
-53
|
-45
|
-36
|
|
| Operating Income |
-42
|
-50
|
-47
|
-55
|
-47
|
-18
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
35
|
29
|
29
|
23
|
20
|
1
|
|
| EPS exc. Extra |
-0.10
|
-1.63
|
-1.52
|
-2.56
|
-2.26
|
-82.66
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
109
|
74
|
112
|
149
|
127
|
157
|
|
| Cash, Eq & Invt ShortTerm |
68
|
69
|
106
|
144
|
122
|
152
|
|
| Total Current Assets |
69
|
70
|
107
|
145
|
123
|
154
|
|
| Total Non-Current Assets |
40
|
4
|
5
|
4
|
4
|
3
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
15
|
14
|
12
|
11
|
9
|
5
|
|
| Total Current Liabilities |
14
|
12
|
9
|
11
|
8
|
3
|
|
| Long Term Debt |
1
|
2
|
3
|
1
|
1
|
1
|
|
| Shareholder equity |
94
|
60
|
101
|
137
|
118
|
153
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-34
|
-38
|
-39
|
-45
|
-35
|
-15
|
|
| Depreciation |
1
|
1
|
1
|
1
|
1
|
0
|
|
| Cash from Investing |
22
|
22
|
-25
|
70
|
34
|
-150
|
|
| Capex |
0
|
0
|
0
|
0
|
2
|
2
|
|
| Cash from Financing |
34
|
0
|
0
|
66
|
7
|
155
|
|
| Stock Issued |
34
|
0
|
0
|
66
|
7
|
64
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
20
|
-23
|
-71
|
20
|
-6
|
-
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
4.9
|
6.0
|
12.4
|
13.7
|
16.2
|
45.5
|
|
| Financial Leverage D/E |
0.02
|
0.05
|
0.04
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-10.5 %
|
-92.9 %
|
-88.4 %
|
-74.6 %
|
-35.6 %
|
-47.8 %
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available